IMR Press / CEOG / Volume 39 / Issue 1 / pii/1630475479187-2145298102

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix
Show Less
1 Oncology Research Institute (IPON), Federal University of Triângulo Mineiro (UFTM), Uberaba, Minas Gerais (Brazil)
2 Oncology Department, University of Hasselt, Diepenbeek (Belgium)
3 Oncology Research Institute (IPON)/Immunology, Federal University of the Triângulo Mineiro (UFTM), Uberaba, MG (Brazil)
4 Oncology Research Institute (Instituto de Pesquisa em Oncologia, IPON)/Gynecology and Obstetrics, Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba, MG (Brazil)
Clin. Exp. Obstet. Gynecol. 2012, 39(1), 27–31;
Published: 10 March 2012
Abstract

Infection with the human papillomavirus virus (HPV) induces innate and acquired immune responses in the cervical stroma, which are a delicate, balanced and generally unpredictable immunological defense. Because of the immunological breaks that the HPV virus causes, eradication of infected cells does not occur, potentially leading to development of intraepithelial and invasive lesions. Advances in our understanding of the immune system and in the definition of antigens in tumor cells has led to many new treatment strategies. As a result, immunotherapy has the potential to be the most specific treatment for tumors, and one that requires elaboration. Recently, immunotherapy with interferon and dendritc cells has been used on intrapepithelial and invasive cervical lesions with promising results.
Keywords
Cervical intraepithelial neoplasia
Human papillomavirus
Immunotherapy
Interferon and dendritc cells
Share
Back to top